Ontogen, Boehringer Ingelheim deal

The companies will collaborate to develop automated hardware and software for high-speed synthesis and purification of chemical compounds for use in drug discovery. Ontogen will receive $41.6 million in R&D and milestone payments over four years. Boehringer Ingelheim will receive exclusive rights to certain technologies, as well as first right of negotiation on drug candidates resulting from Boehringer-funded research. ...